Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+9.7%
5Y CAGR+9.0%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+9.7%/yr
vs +16.7%/yr prior
5Y CAGR
+9.0%/yr
Consistent
Acceleration
-7.0pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
1.5x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$92.45M+17.5%
2024$78.65M+49.0%
2023$52.79M-24.7%
2022$70.06M+49.7%
2021$46.79M-22.0%
2020$60.01M+43.3%
2019$41.88M+11.0%
2018$37.73M+31.7%
2017$28.65M+7.6%
2016$26.62M-